Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma
Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable
- News
- Research
- Sales
- Regulatory
- Healthcare
- Marketing
Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration
There are more than three million people affected by IBD globally, with a need to improve current treatments
Lilly announces acquisition of Ventyx Biosciences for around $1.2bn
Multiple Ventyx drugs are currently in phase 2 development for inflammatory disease
Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma
Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable
AbbVie reaches agreement for affordable prescription drugs with US government
The pharma company has also pledged a $100bn investment in US infrastructure over the next decade
Genentech increases investment to $2bn for US manufacturing site
Roche and Genentech have a current commitment of $50bn for US manufacturing
Latest content
GC Therapeutics appoints Kate Haviland as Board Chair
Haviland was most recently President and CEO of Blueprint Medicines
Read More
Ipsen appoints Pierrick Lefranc as Executive Vice President Technical Operations
Lefranc has served at Ipsen since 2013, most recently as Senior Vice President
Read More
Emotive appoints Terri Cooper as chair of the board and Mark Swindell as non-executive director
Terri and Mark both have extensive life sciences and consulting experience
Read More
Intelligence
Alzheimer’s disease – the future of diagnosis and treatment in Europe
Recognising symptoms early and acting quickly can make a real difference to the lives of patients
Read More
Clinical trials on dementia: bridging access and innovation
Addressing the significant challenges surrounding the accessibility and availability of clinical trials
Read More
The trust crisis: how pharma must evolve to engage Gen Z HCPs
Trust isn’t a campaign outcome; it’s the product of behaviour, language and consistency
Read More
Setting out – why omnichannel success is about orchestration
Today’s audiences listen simultaneously to multiple channels, from social media to digital detailing, which leak into each other like a commuter’s headphones on a crowded train
Read More
Global regulatory standards
The US, EU and UK operate under different systems, with distinct expectations for clinical evidence, timelines and commercial readiness
Read More
Patient insight: human vs AIHCPS
If we’re using AI to inform healthcare decisions, ethical guard rails are essential
Read More
Blogs
Latest
MFN Pricing Is Moving Fast – Here’s What Matters
February 3, 2026 | Genesis Research Group|Access, GENEROUS, GLOBE, GUARD, IRA, Market Access, Pricing, mfn, most favored nation, most-favoured nation
With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it’s a lot …
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
January 27, 2026 | Genesis Research Group|HEOR, Market Access, RWE, Top Trends, ispor, organization
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability …
First impressions matter: Why getting your onboarding right is key for digital engagement
January 20, 2026 | Graphite Digital|Digital engagement in healthcare, HCP onboarding, Healthcare digital transformation, Pharmaceutical digital platforms
As pharma organisations invest extensively in creating engaging content, the onboarding process must not be overlooked. Seamless onboarding is the key to ensuring that HCPs …
How will AI change field training?
January 15, 2026 | Inizio|Generative AI, Intelligent Commercialization
Learn how a next-generation approach to field training – powered by GenAI and avatar simulations and enabled through Intelligent Commercialization™ – can transform field force …
The Heart and Mouth Connection Every Woman Needs to Know
January 9, 2026 | Medscape Education|Women in Leadership, Women in healthcare, podcast
For decades, modern medicine has treated the mouth and the body as separate entities. But for Dr. Nieca Goldberg, a renowned cardiologist, and Dr. Maria …
How can pharma build genuine partnerships with patient communities?
January 19, 2026 | Amiculum|patient advocacy, patient engagement
Patient engagement is not optional in pharma – it’s integral. Meaningful partnerships with patients, caregivers and advocates must shape every stage of healthcare and medicines …
Five Predictions That Will Reshape Biopharma Commercialisation in 2026
January 5, 2026 | Nmblr|
Every year, we’re met with restructuring, hiring freezes, and portfolio cuts. And every year we tell ourselves the same story. It’s a rough patch. A …
What will healthcare communications look like in 2026? Amiculum’s prediction of upcoming trends
December 16, 2025 | Amiculum|AI, JCA, Market Access, Patient-integrated Communications, VuuAI, genAI, healthcare communications, misinformation, omnichannel, trends
By Sarah Theobald
Clinical research in 2026: The trends shaping tomorrow
December 16, 2025 | Cuttsy + Cuttsy|Communications, Decentralised trials, Digital, Pharma, advocacy, clinical trials, partnerships, patient engagement
Discover the key trends shaping clinical research in 2026, from patient-centric approaches to empowering site staff and fostering stronger human connections.
AI persona generation for healthcare: quick wins & real-world impact
December 4, 2025 | Amiculum|AI, Persona generation, Segmentation, artificial intelligence, healthcare communications, omnichannel
By Aaron Fletcher